Cerdulatinib (PRT062070) hydrochloride - 10mM in DMSO, high purity , CAS No.1369761-01-2

Item Number

C421401

• Synonyms: 1369761-01-2 | Cerdulatinib hydrochloride | Cerdulatinib HCl | Cerdulatinib HCl salt | RVT-502 hydrochloride | Cerdulatinib (hydrochloride) | L1KRM66Y4X | 4-(cyclopropylamino)-2-[4-(4-ethylsulfonylpiperazin-1-yl)anilino]pyrimidine-5-carboxamide;hydrochloride | PRT2070 | Ce
• Specifications & Purity: 10mM in DMSO
• Biochemical and Physiological Mechanisms: Cerdulatinib (PRT-062070, PRT2070) hydrochloride is an oral active, multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for JAK1/JAK2/JAK3/TYK2 and Syk, respectively. Also inhibits 19 other tested kinases with IC50 less
• Storage Temp: Store at -80°C
• Shipped In: Ice chest + Ice pads

Product Description

Information

Cerdulatinib (PRT-062070, PRT2070) hydrochloride is an oral active, multi-targeted tyrosine kinase inhibitor withIC50of 12 nM/6 nM/8 nM/0.5 nM and 32 nM forJAK1/JAK2/JAK3/TYK2andSyk, respectively. Also inhibits 19 other tested kinases withIC50less than 200 nM.

Targets

TYK2 (Cell-free assay); MST1 (Cell-free assay); ARK5 (Cell-free assay); MLK1 (Cell-free assay); Fms (Cell-free assay);0.5 nM; 4 nM; 4 nM; 5 nM; 5 nM

In vitro

In human whole blood from normal donors, Cerdulatinib affects BCR-mediated B-cell activation by dual inhibition of SYK and JAK. As a dual SYK/JAK inhibitor, Cerdulatinib significantly reduces cell viability in a subset of NHL cell lines, and induces apoptosis in BCR-signaling competent NHL cell lines.

In vivo

In a rat collagen-induced arthritis model, Cerdulatinib (5 mg/kg p.o.) significantly improves inflammatory infiltrate within the synovium and the integrity of the articular cartilage. In addition, Cerdulatinib also blocks BCR-induced B-cell activation and splenomegaly in mice.

Cell Research(from reference)

Cell lines：Ramos RA-1, Daudi, Toledo, SU-DHL4 and SU-DHL6 cells 

Concentrations：~15 μM 

Incubation Time：72 hours